quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·60d
PRRelease
Avenue Therapeutics Inc. logo
Fortress Biotech Inc. logo

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

ATXI· Avenue Therapeutics Inc.FBIO· Fortress Biotech Inc.
Health Care
Original source

Companies

  • ATXI
    Avenue Therapeutics Inc.
    Health Care
  • FBIO
    Fortress Biotech Inc.
    Health Care

Recent analyst ratings

  • Mar 15FBIOUpdateROTH MKM$10.00
  • Aug 4FBIOUpdateLadenburg Thalmann$6.00

Related

  • PR3d
    Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
  • INSIDER22d
    SEC Form 4 filed by Jin David
  • SEC23d
    SEC Form 10-K filed by Fortress Biotech Inc.
  • SEC23d
    Fortress Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR23d
    Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
  • SEC24d
    SEC Form 10-K filed by Avenue Therapeutics Inc.
  • SEC24d
    Fortress Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR24d
    Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022